These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38791570)

  • 1. Insights into Therapeutic Response Prediction for Ustekinumab in Ulcerative Colitis Using an Ensemble Bioinformatics Approach.
    Koustenis K; Dovrolis N; Viazis N; Ioannou A; Bamias G; Karamanolis G; Gazouli M
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the significance of ECSCR in the diagnosis of ulcerative colitis and drug efficacy assessment.
    Feng B; Zhang Y; Qiao L; Tang Q; Zhang Z; Zhang S; Qiu J; Zhou X; Huang C; Liang Y
    Front Immunol; 2024; 15():1426875. PubMed ID: 39170615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision therapy for ulcerative colitis: insights from mitochondrial dysfunction interacting with the immune microenvironment.
    Zhang YF; Fan MY; Bai QR; Zhao R; Song S; Wu L; Lu JH; Liu JW; Wang Q; Li Y; Chen X
    Front Immunol; 2024; 15():1396221. PubMed ID: 39026683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
    Telesco SE; Brodmerkel C; Zhang H; Kim LL; Johanns J; Mazumder A; Li K; Baribaud F; Curran M; Strauss R; Paxson B; Plevy S; Davison T; Knight L; Dibben S; Schreiber S; Sandborn W; Rutgeerts P; Siegel CA; Reinisch W; Greenbaum LE
    Gastroenterology; 2018 Oct; 155(4):1008-1011.e8. PubMed ID: 29981298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
    Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
    [No Abstract]   [Full Text] [Related]  

  • 6. Can IL-23 be a good target for ulcerative colitis?
    Allocca M; Furfaro F; Fiorino G; Gilardi D; D'Alessio S; Danese S
    Best Pract Res Clin Gastroenterol; 2018; 32-33():95-102. PubMed ID: 30060945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation.
    Li Q; Huang Z; Yang H; Tang J; Zuo T; Yang Q; Huang Z; Guo Q; Li M; Gao X; Chao K
    J Transl Med; 2024 Jun; 22(1):595. PubMed ID: 38926732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.
    Rosen MJ; Karns R; Vallance JE; Bezold R; Waddell A; Collins MH; Haberman Y; Minar P; Baldassano RN; Hyams JS; Baker SS; Kellermayer R; Noe JD; Griffiths AM; Rosh JR; Crandall WV; Heyman MB; Mack DR; Kappelman MD; Markowitz J; Moulton DE; Leleiko NS; Walters TD; Kugathasan S; Wilson KT; Hogan SP; Denson LA
    Gastroenterology; 2017 May; 152(6):1345-1357.e7. PubMed ID: 28132889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration and verification a 13-gene diagnostic framework for ulcerative colitis across multiple platforms via machine learning algorithms.
    Wang J; Li L; Chen P; He C; Niu X
    Sci Rep; 2024 Jul; 14(1):15009. PubMed ID: 38951638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
    BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis.
    Miyoshi J; Matsuura M; Hisamatsu T
    Expert Opin Drug Saf; 2022 Jan; 21(1):1-8. PubMed ID: 34511011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
    Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
    Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy.
    Pavlidis P; Tsakmaki A; Pantazi E; Li K; Cozzetto D; Digby-Bell J; Yang F; Lo JW; Alberts E; Sa ACC; Niazi U; Friedman J; Long AK; Ding Y; Carey CD; Lamb C; Saqi M; Madgwick M; Gul L; Treveil A; Korcsmaros T; Macdonald TT; Lord GM; Bewick G; Powell N
    Nat Commun; 2022 Oct; 13(1):5820. PubMed ID: 36192482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition.
    Magnusson MK; Strid H; Sapnara M; Lasson A; Bajor A; Ung KA; Öhman L
    J Crohns Colitis; 2016 Aug; 10(8):943-52. PubMed ID: 26896085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ustekinumab in treatment of ulcerative colitis: a narrative review.
    Grova M; Vitello A; Mannino M; Casà A; Renna S; Macaluso FS; Orlando A
    Immunotherapy; 2023 Dec; 15(18):1539-1552. PubMed ID: 38018475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study.
    Matsuoka K; Nagano K; Nagasaki S; Murata Y; Hisamatsu T
    BMJ Open; 2022 May; 12(5):e060081. PubMed ID: 35508346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways.
    Low END; Mokhtar NM; Wong Z; Raja Ali RA
    J Crohns Colitis; 2019 May; 13(6):755-763. PubMed ID: 30954025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal IL23A expression predicts the response to Ustekinumab in inflammatory bowel disease.
    Nishioka K; Ogino H; Chinen T; Ihara E; Tanaka Y; Nakamura K; Ogawa Y
    J Gastroenterol; 2021 Nov; 56(11):976-987. PubMed ID: 34448069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
    Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis.
    Morikubo H; Tojima R; Maeda T; Matsuoka K; Matsuura M; Miyoshi J; Tamura S; Hisamatsu T
    Sci Rep; 2024 Feb; 14(1):4386. PubMed ID: 38388662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.